Rania Khedher El Fekih, MD
Nephrology · Boston, MANPI 1689289027
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $937 of the $1,316 with a category attached, or 71.2%. Calliditas Therapeutics US Inc. accounts for 98.6% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $438.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$1K
- AstraZeneca$19
Across 4 payments — averaging $29,921 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$86K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$34K
What the payments were for
- Travel & lodging$93771%
- Food & beverage$37929%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 2 | $1,297 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$1,297
How this compares
$1,316 in reported general payments places this provider in the 70th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolic AcidMycophenolate Sodium | 13 | $6,225 |
| Amlodipine Besylate | 33 | $172 |
| Prednisone | 41 | $165 |
| Torsemide | 11 | $117 |
| Carvedilol | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Leslie FangBoston$388K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Meghan SiseBoston$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.